BHB wanted to replace its project-tracking software, so a BHB Senior Technical Adviser on Information, Communication, and Technology developed similar software in-house. BHB transitioned to the new tool on 01 September 2023. The software tracks the team members’ activities and tasks with respect to start date, due date, completion date, percentage of progress, on track […]
BHB introduces new project-tracking software Read More »
BHB helped the DGDA to develop the Automated Drug Licensing and Renewal System (ADLRS) to digitalize the DGDA’s manual drug licensing system. Based on user experience, BHB is enhancing the software. Because this online system is convenient, medicine shop owners are increasingly using it to submit application for drug licenses. By the end of August
ADLRS use is increasing Read More »
BHB offers an 80-hour refresher training course on GPP to the country’s medicine dispensers who meet certain basic criteria. FCDO provides financial support for this training; 11,577 medicine dispensers have received the refresher training, and an additional 2,500 will be trained by the end of 2023. BHB commissioned ICDDR,B to assess the effects of the
BHB’s e-Learning platform was launched in 2021, and since then, BHB has developed and uploaded 39 different e-courses, with 13 of them available for public access and enrolment. Statistics show that 1,191 individuals have completed one or more of the e-courses. Recently, three new e-courses were added—Basic Principle of Medicine Management, Good Dispensing Practice (GDP),
BHB continues to enrich its e-Learning platform Read More »
The Institute of Health Economics at the University of Dhaka is organizing the International Health Economic Conference 2023 in Dhaka from 12 to 13 September 2023. The event will be held at the Senate Auditorium, Nabab Nawab Ali Chowdhury Senate Bhaban on the university campus. BHB’s donor, the UK Foreign, Commonwealth and Development Office (FCDO),
Antimicrobial resistance (AMR) is a growing global concern. It is widely believed that if the irrational use of antibiotics is not controlled, most antibiotics, including the newer ones, will no longer be effective against bacteria. In addition, because antibiotics yield few or no profit for the pharmaceutical industry, they have little interest in doing research
